355 related articles for article (PubMed ID: 21095544)
1. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators.
Ardill JE; O'Dorisio TM
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):777-90. PubMed ID: 21095544
[TBL] [Abstract][Full Text] [Related]
2. Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
Detjen KM; Rieke S; Deters A; Schulz P; Rexin A; Vollmer S; Hauff P; Wiedenmann B; Pavel M; Scholz A
Clin Cancer Res; 2010 Jan; 16(2):420-9. PubMed ID: 20068079
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
Singh S; Law C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
[TBL] [Abstract][Full Text] [Related]
6. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours.
Oberg K
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S17-25. PubMed ID: 22005113
[No Abstract] [Full Text] [Related]
7. Preface: Gastroenteropancreatic system and its tumors: Part 1.
Vinik AI
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):xvii-xviii. PubMed ID: 21095538
[No Abstract] [Full Text] [Related]
8. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis.
Srirajaskanthan R; Dancey G; Hackshaw A; Luong T; Caplin ME; Meyer T
Endocr Relat Cancer; 2009 Sep; 16(3):967-76. PubMed ID: 19502452
[TBL] [Abstract][Full Text] [Related]
9. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
10. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M
Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
[TBL] [Abstract][Full Text] [Related]
11. New and emerging syndromes due to neuroendocrine tumors.
Vinik AI; Gonzales MR
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):19-63, vii. PubMed ID: 21349410
[TBL] [Abstract][Full Text] [Related]
12. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification.
Klöppel G; Couvelard A; Perren A; Komminoth P; McNicol AM; Nilsson O; Scarpa A; Scoazec JY; Wiedenmann B; Papotti M; Rindi G; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):162-6. PubMed ID: 19060454
[No Abstract] [Full Text] [Related]
13. Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients.
Hilfenhaus G; Göhrig A; Pape UF; Neumann T; Jann H; Zdunek D; Hess G; Stassen JM; Wiedenmann B; Detjen K; Pavel M; Fischer C
Endocr Relat Cancer; 2013 Jun; 20(3):305-19. PubMed ID: 23463017
[TBL] [Abstract][Full Text] [Related]
14. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
15. Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging.
Klimstra DS
Semin Oncol; 2013 Feb; 40(1):23-36. PubMed ID: 23391110
[TBL] [Abstract][Full Text] [Related]
16. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
[TBL] [Abstract][Full Text] [Related]
17. Foreword: Gastroenteropancreatic system and its tumors: Part 1.
LeRoith D
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):xiii-xvi. PubMed ID: 21095537
[No Abstract] [Full Text] [Related]
18. Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors.
Vinik E; Silva MP; Vinik AI
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):97-109, viii. PubMed ID: 21349413
[TBL] [Abstract][Full Text] [Related]
19. [Neuroendocrine tumors of the gastroenteropancreatic system--reevaluation using the Capella classification].
Brüwer M; Pahlov-Nejad T; Herbst H; Senninger N; Schürmann G
Zentralbl Chir; 2003 Aug; 128(8):656-62. PubMed ID: 12931261
[TBL] [Abstract][Full Text] [Related]
20. Sporadically occurring functional pancreatic endocrine tumors: review of recent literature.
Goldin SB; Aston J; Wahi MM
Curr Opin Oncol; 2008 Jan; 20(1):25-33. PubMed ID: 18043253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
